Stockscreener 앱 받기
28.02
0.07%
0.02
시간 외 거래:
28.05
0.03
+0.11%
전일 마감가:
$28.00
열려 있는:
$28.95
하루 거래량:
633.11K
Relative Volume:
0.78
시가총액:
$2.65B
수익:
-
순이익/손실:
$-115.88M
주가수익비율:
-18.11
EPS:
-1.5468
순현금흐름:
$-104.72M
1주 성능:
-0.99%
1개월 성능:
+4.94%
6개월 성능:
+64.53%
1년 성능:
+57.15%
1일 변동 폭
$27.76
$28.95
1주일 범위
$27.01
$29.81
52주 변동 폭
$14.90
$38.12
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
EWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
28.02 | 2.65B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpWhat's Next? - MarketBeat
Moody Aldrich Partners LLC Has $5.02 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 25,000 Shares - MarketBeat
Edgewise Therapeutics names new COO - MSN
Edgewise Therapeutics reshuffles executive team - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.1%Here's What Happened - MarketBeat
Edgewise elevates chief operating officer, hires development exec - BizWest
Edgewise Therapeutics Promotes Behrad Derakhshan, Ph.D., to Chief Operating Officer Role - Defense World
Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? - Insider Monkey
New COOs for Vividion, Edgewise - BioCentury
Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownWhat's Next? - MarketBeat
Edgewise Therapeutics names new COO By Investing.com - Investing.com Australia
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - BioSpace
Edgewise Therapeutics (NASDAQ:EWTX) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Edgewise Therapeutics Strengthens Leadership Team, Appoints Merck Veteran as Chief Development Officer - StockTitan
Edgewise stock rated as a new Hold at Stifel (EWTX:NASDAQ) - Seeking Alpha
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target By Investing.com - Investing.com Canada
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Increases By 8.9% - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Update - MarketBeat
Edgewise Therapeutics Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
JPMorgan Chase & Co. Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Should You Sell? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
December 19th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
How to Take Advantage of moves in (EWTX) - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Trading 7.4% HigherHere's What Happened - MarketBeat
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 - Business Wire
Edgewise Therapeutics Advances Muscular Dystrophy Drug Sevasemten, Nears Pivotal Trial Milestone - StockTitan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - BioSpace
How To Trade (EWTX) - Stock Traders Daily
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells $2,737,000.00 in Stock - MarketBeat
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock - Investing.com India
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data (NASDAQ:EWTX) - Seeking Alpha
Franklin Resources Inc. Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):